Navigation Links
Inverness Medical Innovations Announces Fourth Quarter 2007 Results
Date:2/20/2008

8.9 million charge for the year ended December 31,

2006 includes: $9.5 million charged to cost of sales, $2.9 million

charged to research and development and $0.8 million charged to

selling, general and administrative expense, offset by a $4.3

million net foreign currency gain resulting from the closure of our

CDIL operation in Ireland recorded to other income. These charges

have been excluded from net income or loss because they have a

significant impact on results yet do not occur on a consistent or

regular basis in the Company's business.

(c) Amortization expense of $62.2 million and $21.8 million for the year

2007 and 2006 GAAP results, respectively, including $24.1 million

and $11.2 million charged to cost of sales, $2.9 million and $3.3

million charged to research and development, $34.8 million and $7.1

million charged to selling, general and administrative expense, and

$0.4 million and $0.2 million charged to other expense in the

respective periods.

(d) Compensation costs of $57.4 million and $5.5 million associated with

stock-based compensation expense, including $0.6 million and $0.4

million charged to cost of sales, $2.2 million and $1.4 million

charged to research and development and $54.6 million and $3.7

million charged to selling, general and administrative. The $57.5

million charged to selling, general and administrative during the

year-ended December 31, 2007 includes $45.2 million of costs

associated with stock option acceleration and conversion in

connection with our recent acquisition of Biosite.

(e) A net loss of $3.5 million resulting from a loss of $4.9 million

associated with management's decision to dispose of our SMB research

ope
'/>"/>

SOURCE Inverness Medical Innovations
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Inverness Medical Innovations Completes Acquisition of BBI Holdings Plc
2. Correction to Press Release Dated January 31, 2008: Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
3. Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
4. Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 8, 2008
5. Inverness Medical Innovations Acquires ParadigmHealth
6. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
7. Inverness Medical Innovations Announces Proposed Public Offering of Common Stock
8. Inverness - Chemogen Establish Exclusive License for TB Antibodies
9. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
10. B-Line Medical and Immersion Medical Announce Partnership
11. MIT researcher addresses biomedical engineering challenges
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... (PRWEB) April 21, 2015 Contract Research Organization ... plans to relocate into a new 41,500 ft2 facility. ... headquarters, currently located at 16825 W. 116th St. in Lenexa, ... half times the customized laboratory space, will remain in the ... company was founded more than twenty years ago. Remaining ...
(Date:4/21/2015)... 2015 AbilTo, Inc., the nation,s leading digital ... has been accepted as a presentation to be included ... place on June 5-6, 2015 in Boston, Massachusetts ... Diabetes Association, the cost of diabetes to the American ... result of increased inpatient, outpatient, and pharmacy costs, the ...
(Date:4/21/2015)... 2015 Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) ... on Thursday, April 23, 4:30 p.m. ET. Participants are ... Investor call information: U.S./ ... toll number: (925) 418-7845 Participant Passcode: 32888538 ... Amirkiai , tina.amirkiai@fleishman.com . Access will ...
(Date:4/21/2015)... , April 21, 2015  Tute Genomics, a leading ... of Josh Forsythe as VP of Marketing. Mr. ... witnessed a significant expansion in its commercial operations over the ... " Josh Forsythe is a tremendous addition ... MD MBA, CEO of Tute Genomics. "Josh,s vast experience commercializing ...
Breaking Biology Technology:XenoTech Plans Expansion to New Global Headquarters after Impressive Revenue Growth in 2014 2XenoTech Plans Expansion to New Global Headquarters after Impressive Revenue Growth in 2014 3AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 2AbilTo To Present at the 2015 American Diabetes Association Annual Meeting on Remote Delivery of Behavioral Change Therapy 3Ampio Announces Investor Call on Thursday, April 23, 4:30 p.m. ET 2Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 2Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 3Tute Genomics Continues Expansion of Genomic Medicine Commercial Operations; Appoints Josh Forsythe as New VP of Marketing 4
... ... Position in Automated QT Studies , ... Rochester, New York (PRWEB) October 8, 2009 -- iCardiac Technologies, Inc., ... that an international pharmaceutical company has awarded iCardiac a comprehensive cardiac safety study. ...
... ... Obama , ... Ill. (Vocus) October 7, 2009 -- The IBM Blue Gene series of energy-efficient supercomputers, ... Barack Obama as a Medal of Technology and Innovation award-winner on October 7 in ...
... NEW YORK, Oct. 7 NeoStem, Inc. (NYSE Amex: ... processing and long-term storage of adult stem cells for ... Securities and Exchange Commission has declared effective its Registration ... The Registration Statement, including the joint proxy statement, is ...
Cached Biology Technology:Global Pharmaceutical Company Awards Comprehensive Cardiac Safety Study to iCardiac 2DOE Labs Take Pride in Award-Winning IBM Blue Gene Series 2DOE Labs Take Pride in Award-Winning IBM Blue Gene Series 3DOE Labs Take Pride in Award-Winning IBM Blue Gene Series 4United States Securities and Exchange Commission Declares Effective Registration Statement for NeoStem's Acquisition of China Biopharmaceuticals Holdings, Inc. and a Controlling Interest in Leading Chinese Pharmaceutical Company; Meeting of Each Com 2United States Securities and Exchange Commission Declares Effective Registration Statement for NeoStem's Acquisition of China Biopharmaceuticals Holdings, Inc. and a Controlling Interest in Leading Chinese Pharmaceutical Company; Meeting of Each Com 3United States Securities and Exchange Commission Declares Effective Registration Statement for NeoStem's Acquisition of China Biopharmaceuticals Holdings, Inc. and a Controlling Interest in Leading Chinese Pharmaceutical Company; Meeting of Each Com 4
(Date:4/14/2015)... Conn. , April 14, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... been nominated for the 2015 New York Design Awards ... The Design100, New York City Design Awards are part ... based on over 2,500 ratings from the marketplace, industry ...
(Date:4/10/2015)... 2015 Research and Markets ( ... "Security Competitive Profiles - NEC" report to their ... NEC will continue to supply a range of IT ... a company focus on the development of a Big ... opportunities in the Asia-Pacific region ...
(Date:4/6/2015)... , Apr. 6, 2015 NXT-ID, Inc. ... a biometric authentication company focused on the growing ... filed provisional patent 62/143028 for MINIATURE, ... ENERGY TRANSFER  NXT-ID introduces a new ... This patent surrounds the use of miniature antenna ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3NEC Security Competitive Profile 2015 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4
... to prevailing wisdom, a new study from plant biologists at ... indeed chaperone proteins across the membranes of chloroplasts, just as ... published online in the January issue of the journal ... tasks in a living cell is to move things across ...
... This release is available in Spanish . ... to ethnic minority groups receive worse health care in the ... world,s most developed countries. This conclusion emerges from a research ... most comprehensive bibliographic review worldwide to date on health care ...
... is impacted as much or more by environmental change ... Professor Caryn Vaughn, who serves as director of the ... extinct, we don,t necessarily think of the common species ... Vaughn. "We need to be concerned about these ...
Cached Biology News:Green plant transport mystery solved 2Poorer diabetics receive worse care than other in countries with universal health coverage 2Poorer diabetics receive worse care than other in countries with universal health coverage 3Environmental change impacts Oklahoma rivers 2
Bis-Acrylamide (bis) is a monomer used as a crosslinker with acrylamide to form polyacrylamide electrophoretic gels. This 2% bis solution is supplied as 500 ml....
... EnVision™ G|2 Doublestain System is a ... visualization kit. The kit is intended ... simultaneous detection of two different antigens ... compatible with suitably diluted rabbit and ...
AVOID FREEZE/THAW CYCLES. Recognizes the UCP-2 protein....
Rabbit Anti-Human Janus Kinase 2 (JAK2 Polyclonal Antibody Family: Protein Kinase Sub-Family: TYK2/JAK Applications: ELISA, Western Blot...
Biology Products: